Abordaje del penfigoide ampolloso en paciente de edad avanzada
Palabras clave:
penfigoide ampolloso, enfermedades cutáneas vesiculoampollosas, erupciones por medicamentos
Resumen
Las enfermedades ampollosas en un paciente de edad avanzada representan un reto diagnóstico y terapéutico, entre las cuales se debe considerar al penfigoide ampolloso como una de las más prevalentes. Suele ser más frecuentemente idiopático, aunque hay algunos casos que se asocian a la utilización de ciertos fármacos empleados de forma rutinaria en patologías comunes como diabetes mellitus y enfermedad de Parkinson, además con una relación histórica con ciertas neoplasias.
Presentamos el caso de un paciente de la tercera edad con diagnóstico de penfigoide ampolloso por los hallazgos clínicos confirmados en la anatomía patológica, donde se consideró la etiología farmacológica y neoplásica.
Citas
1. Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol [Internet]. 2022 [cited 2025 Mar 15];36(10):1689–704. Available from: https://pubmed.ncbi.nlm.nih.gov/35766904/
2. Forero E, Chalem M, Vásquez G, Jauregui E, Medina LF, Pinto Peñaranda LF, et al. Gestión de riesgo para la prescripción de terapias biológicas. Rev Colomb Reumatol [Internet]. 2016 [citado 15 Mar 2025];23(1):50–67. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-81232016000100009
3. Liu SD, Chen WT, Chi ChCh. Association between medication use and bullous pemphigoid: A systematic review and meta-analysis. JAMA Dermatol [Internet]. 2020 [cited 2025 Mar 15];156(8):891–900. Available from: https://pubmed.ncbi.nlm.nih.gov/32584924/
4. Cai SCS, Allen JC, Lim YL, Tan SH, Tang MBY. Association of bullous pemphigoid and malignant neoplasms. JAMA Dermatol [Internet]. 2015 [cited 2025 Mar 15];151(6):665–7. Available from: https://jamanetwork.com/journals/jamadermatology/fullarticle/2110015
5. Atzmony L, Mimouni I, Reiter O, Leshem YA, Taha O, Gdalevich M, et al. Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis. J Am Acad Dermatol [Internet]. 2017 [cited 2025 Dec 15];77(4):691–9. Available from: http://dx.doi.org/10.1016/j.jaad.2017.05.006 Subscription required
6. Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol [Internet]. 2016 [cited 2025 Dec 15];30(12):2007–15. Available from: http://dx.doi.org/10.1111/jdv.13660 Subscription required
7. Siranart N, Chumpangern Y, Phutinart S, Pajareya P, Worapongpaiboon R, Winson Ch, et al. Chronic disease associated with bullous pemphigoid risk: A systematic review and meta-analysis. JAAD Int [Internet]. 2024 [cited 2025 Dec 15];17:141–52. Available from: https://pubmed.ncbi.nlm.nih.gov/39444540/
8. Granados-Betancort E, Sánchez-Díaz M, Muñoz-Barba D, Arias-Santiago S. Omalizumab and dupilumab for the treatment of bullous pemphigoid: A systematic review. J Clin Med [Internet]. 2024 [cited 2025 Dec 15];13(16):4844. Available from: https://pubmed.ncbi.nlm.nih.gov/39200987/
2. Forero E, Chalem M, Vásquez G, Jauregui E, Medina LF, Pinto Peñaranda LF, et al. Gestión de riesgo para la prescripción de terapias biológicas. Rev Colomb Reumatol [Internet]. 2016 [citado 15 Mar 2025];23(1):50–67. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-81232016000100009
3. Liu SD, Chen WT, Chi ChCh. Association between medication use and bullous pemphigoid: A systematic review and meta-analysis. JAMA Dermatol [Internet]. 2020 [cited 2025 Mar 15];156(8):891–900. Available from: https://pubmed.ncbi.nlm.nih.gov/32584924/
4. Cai SCS, Allen JC, Lim YL, Tan SH, Tang MBY. Association of bullous pemphigoid and malignant neoplasms. JAMA Dermatol [Internet]. 2015 [cited 2025 Mar 15];151(6):665–7. Available from: https://jamanetwork.com/journals/jamadermatology/fullarticle/2110015
5. Atzmony L, Mimouni I, Reiter O, Leshem YA, Taha O, Gdalevich M, et al. Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis. J Am Acad Dermatol [Internet]. 2017 [cited 2025 Dec 15];77(4):691–9. Available from: http://dx.doi.org/10.1016/j.jaad.2017.05.006 Subscription required
6. Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol [Internet]. 2016 [cited 2025 Dec 15];30(12):2007–15. Available from: http://dx.doi.org/10.1111/jdv.13660 Subscription required
7. Siranart N, Chumpangern Y, Phutinart S, Pajareya P, Worapongpaiboon R, Winson Ch, et al. Chronic disease associated with bullous pemphigoid risk: A systematic review and meta-analysis. JAAD Int [Internet]. 2024 [cited 2025 Dec 15];17:141–52. Available from: https://pubmed.ncbi.nlm.nih.gov/39444540/
8. Granados-Betancort E, Sánchez-Díaz M, Muñoz-Barba D, Arias-Santiago S. Omalizumab and dupilumab for the treatment of bullous pemphigoid: A systematic review. J Clin Med [Internet]. 2024 [cited 2025 Dec 15];13(16):4844. Available from: https://pubmed.ncbi.nlm.nih.gov/39200987/
